Cardiac Calcitropes, Myotropes, and Mitotropes: JACC Review Topic of the Week

Mitchell A. Psotka, Stephen S. Gottlieb, Gary S Francis, Larry A. Allen, John R. Teerlink, Kirkwood F. Adams, Giuseppe M.C. Rosano, Patrizio Lancellotti

Research output: Contribution to journalReview article

Abstract

The term “inotrope” is familiar and intimately connected with pharmaceuticals clinically used for treatment of low cardiac output with cardiogenic shock. Traditional inotropic agents exert their effect by modulating calcium signaling in the myocardium. Their use is associated with poor long-term outcomes. Newer molecules in development intend to break from calcium mediation and the associated detrimental long-term effects by targeting distinct mechanisms of action to improve cardiac performance. Thus, “inotropy” does not sufficiently describe the range of potential novel pharmaceutical products. To enhance communication around and evaluation of current, emerging, and potential therapies, this review proposes a novel nuanced and holistic framework to categorize pharmacological agents that improve myocardial performance based on 3 myocardial mechanisms: calcitropes, which alter intracellular calcium concentrations; myotropes, which affect the molecular motor and scaffolding; and mitotropes, which influence energetics. Novel chemical entities can easily be incorporated into this structure, distinguishing themselves based on their mechanisms and clinical outcomes.

Original languageEnglish (US)
Pages (from-to)2345-2353
Number of pages9
JournalJournal of the American College of Cardiology
Volume73
Issue number18
DOIs
StatePublished - May 14 2019

Fingerprint

Calcium
Low Cardiac Output
Calcium Signaling
Cardiogenic Shock
Pharmaceutical Preparations
Myocardium
Pharmacology
Therapeutics

Keywords

  • cardiac contractility
  • heart failure
  • inotrope
  • systolic function

Cite this

Psotka, M. A., Gottlieb, S. S., Francis, G. S., Allen, L. A., Teerlink, J. R., Adams, K. F., ... Lancellotti, P. (2019). Cardiac Calcitropes, Myotropes, and Mitotropes: JACC Review Topic of the Week. Journal of the American College of Cardiology, 73(18), 2345-2353. https://doi.org/10.1016/j.jacc.2019.02.051

Cardiac Calcitropes, Myotropes, and Mitotropes : JACC Review Topic of the Week. / Psotka, Mitchell A.; Gottlieb, Stephen S.; Francis, Gary S; Allen, Larry A.; Teerlink, John R.; Adams, Kirkwood F.; Rosano, Giuseppe M.C.; Lancellotti, Patrizio.

In: Journal of the American College of Cardiology, Vol. 73, No. 18, 14.05.2019, p. 2345-2353.

Research output: Contribution to journalReview article

Psotka, MA, Gottlieb, SS, Francis, GS, Allen, LA, Teerlink, JR, Adams, KF, Rosano, GMC & Lancellotti, P 2019, 'Cardiac Calcitropes, Myotropes, and Mitotropes: JACC Review Topic of the Week', Journal of the American College of Cardiology, vol. 73, no. 18, pp. 2345-2353. https://doi.org/10.1016/j.jacc.2019.02.051
Psotka, Mitchell A. ; Gottlieb, Stephen S. ; Francis, Gary S ; Allen, Larry A. ; Teerlink, John R. ; Adams, Kirkwood F. ; Rosano, Giuseppe M.C. ; Lancellotti, Patrizio. / Cardiac Calcitropes, Myotropes, and Mitotropes : JACC Review Topic of the Week. In: Journal of the American College of Cardiology. 2019 ; Vol. 73, No. 18. pp. 2345-2353.
@article{3e5568d121c5460cb04529859d783bb1,
title = "Cardiac Calcitropes, Myotropes, and Mitotropes: JACC Review Topic of the Week",
abstract = "The term “inotrope” is familiar and intimately connected with pharmaceuticals clinically used for treatment of low cardiac output with cardiogenic shock. Traditional inotropic agents exert their effect by modulating calcium signaling in the myocardium. Their use is associated with poor long-term outcomes. Newer molecules in development intend to break from calcium mediation and the associated detrimental long-term effects by targeting distinct mechanisms of action to improve cardiac performance. Thus, “inotropy” does not sufficiently describe the range of potential novel pharmaceutical products. To enhance communication around and evaluation of current, emerging, and potential therapies, this review proposes a novel nuanced and holistic framework to categorize pharmacological agents that improve myocardial performance based on 3 myocardial mechanisms: calcitropes, which alter intracellular calcium concentrations; myotropes, which affect the molecular motor and scaffolding; and mitotropes, which influence energetics. Novel chemical entities can easily be incorporated into this structure, distinguishing themselves based on their mechanisms and clinical outcomes.",
keywords = "cardiac contractility, heart failure, inotrope, systolic function",
author = "Psotka, {Mitchell A.} and Gottlieb, {Stephen S.} and Francis, {Gary S} and Allen, {Larry A.} and Teerlink, {John R.} and Adams, {Kirkwood F.} and Rosano, {Giuseppe M.C.} and Patrizio Lancellotti",
year = "2019",
month = "5",
day = "14",
doi = "10.1016/j.jacc.2019.02.051",
language = "English (US)",
volume = "73",
pages = "2345--2353",
journal = "Journal of the American College of Cardiology.",
issn = "0735-1097",
publisher = "Elsevier USA",
number = "18",

}

TY - JOUR

T1 - Cardiac Calcitropes, Myotropes, and Mitotropes

T2 - JACC Review Topic of the Week

AU - Psotka, Mitchell A.

AU - Gottlieb, Stephen S.

AU - Francis, Gary S

AU - Allen, Larry A.

AU - Teerlink, John R.

AU - Adams, Kirkwood F.

AU - Rosano, Giuseppe M.C.

AU - Lancellotti, Patrizio

PY - 2019/5/14

Y1 - 2019/5/14

N2 - The term “inotrope” is familiar and intimately connected with pharmaceuticals clinically used for treatment of low cardiac output with cardiogenic shock. Traditional inotropic agents exert their effect by modulating calcium signaling in the myocardium. Their use is associated with poor long-term outcomes. Newer molecules in development intend to break from calcium mediation and the associated detrimental long-term effects by targeting distinct mechanisms of action to improve cardiac performance. Thus, “inotropy” does not sufficiently describe the range of potential novel pharmaceutical products. To enhance communication around and evaluation of current, emerging, and potential therapies, this review proposes a novel nuanced and holistic framework to categorize pharmacological agents that improve myocardial performance based on 3 myocardial mechanisms: calcitropes, which alter intracellular calcium concentrations; myotropes, which affect the molecular motor and scaffolding; and mitotropes, which influence energetics. Novel chemical entities can easily be incorporated into this structure, distinguishing themselves based on their mechanisms and clinical outcomes.

AB - The term “inotrope” is familiar and intimately connected with pharmaceuticals clinically used for treatment of low cardiac output with cardiogenic shock. Traditional inotropic agents exert their effect by modulating calcium signaling in the myocardium. Their use is associated with poor long-term outcomes. Newer molecules in development intend to break from calcium mediation and the associated detrimental long-term effects by targeting distinct mechanisms of action to improve cardiac performance. Thus, “inotropy” does not sufficiently describe the range of potential novel pharmaceutical products. To enhance communication around and evaluation of current, emerging, and potential therapies, this review proposes a novel nuanced and holistic framework to categorize pharmacological agents that improve myocardial performance based on 3 myocardial mechanisms: calcitropes, which alter intracellular calcium concentrations; myotropes, which affect the molecular motor and scaffolding; and mitotropes, which influence energetics. Novel chemical entities can easily be incorporated into this structure, distinguishing themselves based on their mechanisms and clinical outcomes.

KW - cardiac contractility

KW - heart failure

KW - inotrope

KW - systolic function

UR - http://www.scopus.com/inward/record.url?scp=85064687087&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064687087&partnerID=8YFLogxK

U2 - 10.1016/j.jacc.2019.02.051

DO - 10.1016/j.jacc.2019.02.051

M3 - Review article

C2 - 31072579

AN - SCOPUS:85064687087

VL - 73

SP - 2345

EP - 2353

JO - Journal of the American College of Cardiology.

JF - Journal of the American College of Cardiology.

SN - 0735-1097

IS - 18

ER -